The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Current evidence does not recommend thoracic radiotherapy for esSCLC
Bjorn Henning Gronberg, MD, PhD, Norwegian University of Science and Technology, Trondheim, Norway, explores the current evidence base for thoracic radiotherapy in extensive-stage small cell lung cancer (esSCLC) in the immunotherapy era, highlighting that recent studies have shown no indication of benefit and increased fatal events with the addition of thoracic radiotherapy to chemoimmunotherapy. Evidence suggests therefore that thoracic radiotherapy should not be offered to patients with patients esSCLC receiving chemoimmunotherapy, except for those with symptomatic tumor progression who may benefit from palliative radiotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
